肿瘤细胞治疗研究
FRONTIER PAPERS
Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting.
本通讯重点介绍了 2025 ASH 年会上报告的免疫性血小板减少症 (ITP) 新兴免疫靶向疗法。
Depletion of the RNA-Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells.
功能性耗竭和低效的肿瘤浸润率限制了基于自然杀伤（NK）细胞的癌症免疫疗法的有效性。
Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8(+) T cell activation in patients with advanced colorectal cancer.
9 例患者中有 3 例达到疾病稳定，疾病控制率为 33.3%。
LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells.
根据这些结果，LLT1 过表达增强了 UCAR-T 细胞的活性并防止同种异体排斥反应，为通用型 CAR-T 细胞疗法的开发提供了重要见解。
Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chi
这些发现支持进一步研究再治疗策略和CAR-T后维持治疗方法。
Intratumoral CD38(+)CD19(+)B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma.
我们发现调节性 B 细胞样 CD38⁺ B 细胞浸润是胰腺导管腺癌（PDAC）的独立预后因素。
CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
这些结果支持了 CD38 CAR-T/NK 对 T-ALL 的疗效，并证明“二合一”策略能够解决自相残杀问题并增强肿瘤清除，为临床转化铺平了道路。
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myelom
我们比较了BCMA CAR-T治疗前和BCMA CAR-T治疗后复发时CD45 + BM细胞的异质性。
All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.
本研究阐明了 ATRA 调控 CD38 表达的一种机制，并拓展了 ATRA 在改善多发性骨髓瘤患者抗 CD38 免疫治疗方面的临床潜力。Cite Now.
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.
CD38在多发性骨髓瘤（MM）细胞上高表达，并在调控肿瘤发生发展中发挥作用。
MEMBER ACCOUNT
登录成功会直接打开下一页。
